TREMFYA® Long-Term Study Shows Significant Efficacy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy JNJ?
Source: PRnewswire
- Clinical Remission Rate Increase: In the QUASAR long-term extension study, 80.8% of patients treated with TREMFYA® achieved clinical remission by Week 140, demonstrating the drug's sustained efficacy in treating adults with moderately to severely active ulcerative colitis, thereby enhancing patients' quality of life.
- Significant Endoscopic Remission: The study revealed that 53.6% of patients achieved endoscopic remission at Week 140, with 78.6% showing histo-endoscopic mucosal improvement, indicating TREMFYA®'s effectiveness in improving gut health and potentially reducing future flare-up risks for patients.
- High Treatment Completion Rate: Approximately 89% of eligible participants completed treatment through Week 140, reflecting good tolerability and adherence to TREMFYA®, which further strengthens confidence in the long-term use of this medication.
- No New Safety Concerns: The study reported no new safety issues, and 87.5% of patients who achieved clinical remission at Week 44 maintained it through Week 140, indicating the sustained efficacy of TREMFYA® regardless of prior treatment history.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 246.910
Low
190.00
Averages
218.50
High
240.00
Current: 246.910
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson Invests Over $1 Billion in Pennsylvania
- Massive Investment: Johnson & Johnson has announced an investment of over $1 billion in a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania, which is expected to create over 500 biomanufacturing jobs and 4,000 construction jobs, significantly boosting the local economy.
- Significant Economic Impact: This investment is part of the company's broader $55 billion commitment to U.S. investments by 2029, aimed at enhancing its manufacturing capacity in the U.S. to meet the needs of patients, thereby increasing the company's competitiveness in the global market.
- Innovative Manufacturing Capability: The new facility will utilize cutting-edge cell therapy technologies to support Johnson & Johnson's portfolio of transformational medicines for cancer, immune-mediated, and neurological diseases, further solidifying its leadership in the life sciences sector.
- Local Government Support: The Governor of Pennsylvania highlighted that the state's leadership in life sciences and advanced manufacturing has attracted companies like Johnson & Johnson to increase their investments, demonstrating effective execution of the state's economic development plan and strategic investments in key industries.
See More
Johnson & Johnson Reports Long-Term TREMFYA Study Results
- Significant Clinical Remission: In the QUASAR long-term extension study, 80.8% of patients receiving TREMFYA achieved clinical remission by Week 140, demonstrating the drug's efficacy and durability in treating moderately to severely active ulcerative colitis.
- High Tissue Improvement Rates: The study revealed that 78.6% of patients reached histo-endoscopic mucosal improvement (HEMI) at Week 140, while 53.6% achieved endoscopic remission, indicating TREMFYA's substantial impact on improving patients' pathological conditions.
- High Treatment Completion Rate: Approximately 89% of eligible participants completed treatment through Week 140, with nearly all patients in clinical remission at this timepoint being corticosteroid-free for at least eight weeks, showcasing the treatment's safety and tolerability.
- Strong Durability of Efficacy: Among those in clinical remission at Week 44, 87.5% maintained remission through Week 140, with efficacy remaining consistent regardless of prior biologic or JAK inhibitor treatment history, and no new safety concerns identified during the study.
See More
TREMFYA® Long-Term Study Shows Significant Efficacy
- Clinical Remission Rate Increase: In the QUASAR long-term extension study, 80.8% of patients treated with TREMFYA® achieved clinical remission by Week 140, demonstrating the drug's sustained efficacy in treating adults with moderately to severely active ulcerative colitis, thereby enhancing patients' quality of life.
- Significant Endoscopic Remission: The study revealed that 53.6% of patients achieved endoscopic remission at Week 140, with 78.6% showing histo-endoscopic mucosal improvement, indicating TREMFYA®'s effectiveness in improving gut health and potentially reducing future flare-up risks for patients.
- High Treatment Completion Rate: Approximately 89% of eligible participants completed treatment through Week 140, reflecting good tolerability and adherence to TREMFYA®, which further strengthens confidence in the long-term use of this medication.
- No New Safety Concerns: The study reported no new safety issues, and 87.5% of patients who achieved clinical remission at Week 44 maintained it through Week 140, indicating the sustained efficacy of TREMFYA® regardless of prior treatment history.
See More
TREMFYA® Long-Term Study Shows Significant Efficacy
- Clinical Remission Rate: In the QUASAR long-term extension study, 80.8% of patients treated with TREMFYA® achieved clinical remission by Week 140, demonstrating the drug's sustained efficacy in treating adults with moderately to severely active ulcerative colitis, thereby enhancing patient quality of life.
- Significant Endoscopic Remission: The study revealed that 53.6% of patients reached endoscopic remission at Week 140, with 78.6% achieving histo-endoscopic mucosal improvement, indicating TREMFYA®'s effectiveness in improving gut health and potentially reducing future flare-up risks for patients.
- High Treatment Completion Rate: Approximately 89% of eligible participants completed treatment through Week 140, reflecting good tolerability and adherence to TREMFYA®, which further strengthens confidence in its long-term use.
- No New Safety Concerns: The study reported no new safety issues, with 87.5% of patients maintaining clinical remission from Week 44 to Week 140, indicating TREMFYA®'s efficacy and safety across different treatment histories, supporting its broader clinical application.
See More
Johnson & Johnson Plans to Sell Orthopedics Unit DePuy Synthes
- Separation Strategy: Johnson & Johnson plans to separate its orthopedics unit, DePuy Synthes, within 18 to 24 months to enhance strategic and operational focus, potentially through a sale or other transactions to realize greater value.
- Acquisition Potential: Bloomberg reports that DePuy Synthes could be valued at approximately $20 billion, or $28 billion including debt, attracting interest from several large private equity firms considering joint bids.
- Strong Financial Performance: DePuy Synthes generated $9.3 billion in annual sales, while Johnson & Johnson reported adjusted earnings of $2.46 per share for Q4 2025, a 20.6% year-over-year increase, surpassing the consensus estimate of $2.44.
- Positive Market Reaction: Johnson & Johnson's stock rose 0.78% to $246.91 on Thursday, reflecting investor optimism regarding the company's separation plans and future growth potential.
See More
RYBREVANTFASPRO™ Shows Significant Antitumor Activity in HNSCC
- Enhanced Clinical Response: In the OrigAMI-4 study, the combination of RYBREVANTFASPRO™ with a PD-1 inhibitor achieved a confirmed overall response rate of 56% in first-line treatment patients, significantly surpassing the historical 18% response rate of standard therapies, indicating its substantial potential in treating recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
- Rapid Response Time: The median time to first response was 9.7 weeks, with 46% of patients remaining on treatment at a median follow-up of 10.4 months, demonstrating that this therapy not only rapidly controls disease but also offers durable treatment effects, potentially altering patient prognosis.
- High Tumor Shrinkage Rate: Among treated patients, 82% experienced tumor shrinkage of target lesions, and a clinical benefit rate of 74% (confirmed responses or durable stable disease) further validates the efficacy of this therapy, potentially providing new treatment options for HNSCC patients.
- Good Safety Profile: The safety profile of RYBREVANTFASPRO™ was consistent with that of the individual agents, with no new safety signals identified; although 49% of patients experienced adverse reactions such as rash, most were mild, indicating the therapy's acceptability and tolerability.
See More
Johnson & Johnson Invests Over $1 Billion in Pennsylvania
- Massive Investment: Johnson & Johnson has announced an investment of over $1 billion in a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania, which is expected to create over 500 biomanufacturing jobs and 4,000 construction jobs, significantly boosting the local economy.
- Significant Economic Impact: This investment is part of the company's broader $55 billion commitment to U.S. investments by 2029, aimed at enhancing its manufacturing capacity in the U.S. to meet the needs of patients, thereby increasing the company's competitiveness in the global market.
- Innovative Manufacturing Capability: The new facility will utilize cutting-edge cell therapy technologies to support Johnson & Johnson's portfolio of transformational medicines for cancer, immune-mediated, and neurological diseases, further solidifying its leadership in the life sciences sector.
- Local Government Support: The Governor of Pennsylvania highlighted that the state's leadership in life sciences and advanced manufacturing has attracted companies like Johnson & Johnson to increase their investments, demonstrating effective execution of the state's economic development plan and strategic investments in key industries.
See More
Johnson & Johnson Reports Long-Term TREMFYA Study Results
- Significant Clinical Remission: In the QUASAR long-term extension study, 80.8% of patients receiving TREMFYA achieved clinical remission by Week 140, demonstrating the drug's efficacy and durability in treating moderately to severely active ulcerative colitis.
- High Tissue Improvement Rates: The study revealed that 78.6% of patients reached histo-endoscopic mucosal improvement (HEMI) at Week 140, while 53.6% achieved endoscopic remission, indicating TREMFYA's substantial impact on improving patients' pathological conditions.
- High Treatment Completion Rate: Approximately 89% of eligible participants completed treatment through Week 140, with nearly all patients in clinical remission at this timepoint being corticosteroid-free for at least eight weeks, showcasing the treatment's safety and tolerability.
- Strong Durability of Efficacy: Among those in clinical remission at Week 44, 87.5% maintained remission through Week 140, with efficacy remaining consistent regardless of prior biologic or JAK inhibitor treatment history, and no new safety concerns identified during the study.
See More
TREMFYA® Long-Term Study Shows Significant Efficacy
- Clinical Remission Rate Increase: In the QUASAR long-term extension study, 80.8% of patients treated with TREMFYA® achieved clinical remission by Week 140, demonstrating the drug's sustained efficacy in treating adults with moderately to severely active ulcerative colitis, thereby enhancing patients' quality of life.
- Significant Endoscopic Remission: The study revealed that 53.6% of patients achieved endoscopic remission at Week 140, with 78.6% showing histo-endoscopic mucosal improvement, indicating TREMFYA®'s effectiveness in improving gut health and potentially reducing future flare-up risks for patients.
- High Treatment Completion Rate: Approximately 89% of eligible participants completed treatment through Week 140, reflecting good tolerability and adherence to TREMFYA®, which further strengthens confidence in the long-term use of this medication.
- No New Safety Concerns: The study reported no new safety issues, and 87.5% of patients who achieved clinical remission at Week 44 maintained it through Week 140, indicating the sustained efficacy of TREMFYA® regardless of prior treatment history.
See More
TREMFYA® Long-Term Study Shows Significant Efficacy
- Clinical Remission Rate: In the QUASAR long-term extension study, 80.8% of patients treated with TREMFYA® achieved clinical remission by Week 140, demonstrating the drug's sustained efficacy in treating adults with moderately to severely active ulcerative colitis, thereby enhancing patient quality of life.
- Significant Endoscopic Remission: The study revealed that 53.6% of patients reached endoscopic remission at Week 140, with 78.6% achieving histo-endoscopic mucosal improvement, indicating TREMFYA®'s effectiveness in improving gut health and potentially reducing future flare-up risks for patients.
- High Treatment Completion Rate: Approximately 89% of eligible participants completed treatment through Week 140, reflecting good tolerability and adherence to TREMFYA®, which further strengthens confidence in its long-term use.
- No New Safety Concerns: The study reported no new safety issues, with 87.5% of patients maintaining clinical remission from Week 44 to Week 140, indicating TREMFYA®'s efficacy and safety across different treatment histories, supporting its broader clinical application.
See More
Johnson & Johnson Plans to Sell Orthopedics Unit DePuy Synthes
- Separation Strategy: Johnson & Johnson plans to separate its orthopedics unit, DePuy Synthes, within 18 to 24 months to enhance strategic and operational focus, potentially through a sale or other transactions to realize greater value.
- Acquisition Potential: Bloomberg reports that DePuy Synthes could be valued at approximately $20 billion, or $28 billion including debt, attracting interest from several large private equity firms considering joint bids.
- Strong Financial Performance: DePuy Synthes generated $9.3 billion in annual sales, while Johnson & Johnson reported adjusted earnings of $2.46 per share for Q4 2025, a 20.6% year-over-year increase, surpassing the consensus estimate of $2.44.
- Positive Market Reaction: Johnson & Johnson's stock rose 0.78% to $246.91 on Thursday, reflecting investor optimism regarding the company's separation plans and future growth potential.
See More
RYBREVANTFASPRO™ Shows Significant Antitumor Activity in HNSCC
- Enhanced Clinical Response: In the OrigAMI-4 study, the combination of RYBREVANTFASPRO™ with a PD-1 inhibitor achieved a confirmed overall response rate of 56% in first-line treatment patients, significantly surpassing the historical 18% response rate of standard therapies, indicating its substantial potential in treating recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
- Rapid Response Time: The median time to first response was 9.7 weeks, with 46% of patients remaining on treatment at a median follow-up of 10.4 months, demonstrating that this therapy not only rapidly controls disease but also offers durable treatment effects, potentially altering patient prognosis.
- High Tumor Shrinkage Rate: Among treated patients, 82% experienced tumor shrinkage of target lesions, and a clinical benefit rate of 74% (confirmed responses or durable stable disease) further validates the efficacy of this therapy, potentially providing new treatment options for HNSCC patients.
- Good Safety Profile: The safety profile of RYBREVANTFASPRO™ was consistent with that of the individual agents, with no new safety signals identified; although 49% of patients experienced adverse reactions such as rash, most were mild, indicating the therapy's acceptability and tolerability.
See More
